公开(公告)号：WO2009117626A3

公开(公告)日：2009-12-23

申请号：PCT/US2009037741

申请日：2009-03-20

Applicant: ABBOTT LAB ,  LUKIN KIRILL A ,  KOTECKI BRIAN J ,  YU SU ,  WANG LEI ,  HAIGHT ANTHONY R

Inventor： LUKIN KIRILL A ,  KOTECKI BRIAN J ,  YU SU ,  WANG LEI ,  HAIGHT ANTHONY R

IPC: C07D231/56 ,  C07D231/54

CPC classification number: C07D231/56

Abstract: The invention discloses compounds of formula ( II ): and methods of making the compounds, which are VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Abstract translation: 本发明公开了式（II）的化合物：以及制备可用于治疗疼痛，炎症性热痛觉过敏，尿失禁和膀胱过度活动的VR1拮抗剂的化合物的方法。

公开(公告)号：EP2323989A4

公开(公告)日：2011-06-22

申请号：EP09722850

申请日：2009-03-20

Applicant: ABBOTT LAB

Inventor： LUKIN KIRILL A ,  KOTECKI BRIAN J ,  YU SU ,  WANG LEI ,  HAIGHT ANTHONY R

IPC: C07D231/56

CPC classification number: C07D231/56

公开(公告)号：BRPI0816994A2

公开(公告)日：2015-03-24

申请号：BRPI0816994

申请日：2008-09-17

Applicant: ABBOTT LAB

Inventor： ROLF WAGNER ,  TUFANO MICHAEL D ,  STEWART KENT D ,  ROCKWAY TODD W ,  RANDOLPH JOHN T ,  PRATT JOHN K ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LONGENECKER KENTON L ,  LIU YAYA ,  LIU DACHUN ,  KRUEGER ALLAN C ,  KATI WARREN M ,  HUTCHINSON DOUGLAS K ,  HUANG PEGGY P ,  FLENTGE CHARLES A ,  DONNER PAMELA L ,  DEGOEY DAVID A ,  BETEBENNER DAVID A ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  SARRIS KATHY ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/513 ,  A61P31/12 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

公开(公告)号：NZ589732A

公开(公告)日：2012-08-31

申请号：NZ58973209

申请日：2009-06-18

Applicant: ABBOTT LAB

Inventor： FRANCZYK THADDEUS S ,  HILL DAVID R ,  HAIGHT ANTHONY R ,  MCLAUGLIN MAUREEN ANN ,  SHEKHAR SHASHANK ,  YU SU ,  MEI JIANZHANG ,  WANG LEI

IPC: C07D295/155 ,  C07D295/023

Abstract: Disclosed A process for making ABT-263 (7) an apoptosis promoter having the proper chemical name: N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, comprising: (a) reacting 4,4-dimethylcyclohexanone, an alkyl formate and a first base to provide (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone and isolating or not isolating the (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone; (b) reacting the (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone, a second base and a first silyl ether protecting group reagent to provide a first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone and isolating or not isolating the first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone; (c) reacting the first protected (2E)-2-(hydroxymethylene)-4,4-dimethylcyclohexanone and 4-chlorophenyl magnesium bromide to provide the first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)-4,4-dimethylcyclohexanol; and isolating or not isolating the first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)4,4-dimethylcyclohexanol; and (d) reacting the first protected (2E)-1-(4-chlorophenyl)-2-(hydroxymethylene)-4,4-dimethylcyclohexanol and a first acid to provide 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde and isolating or not isolating the 2-(4-chlorophenyl)5,5-dimethylcyclohex-1-ene-1-carbaldehyde; (e) reacting 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde, ethyl 4-piperazin-1-ylbenzoate and a first reducing agent and isolating or not isolating the ethyl 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoate; (f) reacting ethyl 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoate and an aqueous third base, and isolating or not isolating the 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoic acid; and (g) reacting 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoic acid, 4-(((1R)-3-morpholin-4-yl-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, a first coupling reagent, and, optionally; a first auxiliary coupling reagent and isolating or not isolating the N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1- ((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide.

公开(公告)号：NZ584720A

公开(公告)日：2012-07-27

申请号：NZ58472008

申请日：2008-09-17

Applicant: ABBOTT LAB

Inventor： FRANCZYK THADDEUS S ,  WAGNER ROLF ,  TUFANO MICHAEL D ,  STEWART KENT D ,  ROCKWAY TODD W ,  RANDOLPH JOHN T ,  PRATT JOHN K ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LONGENECKER KENTON L ,  LIU YAYA ,  LIU DACHUN ,  KRUEGER ALLAN C ,  KATI WARREN M ,  HUTCHINSON DOUGLAS K ,  HUANG PEGGY P ,  FLENTGE CHARLES A ,  DONNER PAMELA L ,  DEGOEY DAVID A ,  BETEBENNER DAVID A ,  BARNES DAVID M ,  CHEN SHUANG ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  SARRIS KATHY ,  ZHANG GEOFF G

IPC: C07D417/10 ,  A61K31/513 ,  A61P31/12 ,  C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10

Abstract: Disclosed are Uracil or Thymine derivatives of formula (I) examples of which are: (E)-N-(4-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide; (E)-N-(4-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide (Z)-N-(4-(2-(3-tert-butyl-5-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-2-methoxyphenyl)-1-chlorovinyl)phenyl)methanesulfonamide; (E)-1-(3-tert-butyl-5-(4-fluorostyryl)-4-methoxyphenyl) dihydropyrimidine-2,4(1H,3H)-dione; The compounds are for use in treating Hepatitis C

公开(公告)号：UA97639C2

公开(公告)日：2012-03-12

申请号：UAA200811465

申请日：2007-02-16

Applicant: ABBOTT LAB

Inventor： COWART MARLON D ,  ZHAO CHEN ,  SUN MINGHUA ,  BLACK LAWRENCE A ,  ZHENG GUO ZHU ,  GREGG ROBERT J ,  ZHANG GEOFF G Z ,  SHEIKH AHMAD Y ,  LOU XIAOCHUN ,  HENRY RODGER F ,  BARNES DAVID M ,  KOLACZKOWSKI LAWRENCE ,  HAIGHT ANTHONY R ,  CHANG SOU-JEN ,  WITTENBERGER STEVEN J ,  FICKES MICHAEL G

IPC: C07D487/04 ,  A61K31/407

Abstract: Раскрытыоктагидропирроло[3,4-b]пиррольныепроизводныеформулы I и II, пригодныедлялечениясостоянийилирасстройств, которыепредотвращаютсяилиоблегчаютсяс помощьюлигандоврецепторагистамина-3.Раскрытыоктагидропирроло[3,4-b]пиррольныесоединения, применениетакихсоединений, композиции, содержащиеэтисоединения, испособыполучениятакихсоединений.

公开(公告)号：DK2203431T3

公开(公告)日：2011-11-21

申请号：DK08832330

申请日：2008-09-17

Applicant: ABBOTT LAB

Inventor： FLENTGE CHARLES A ,  HUTCHINSON DOUGLAS K ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  DONNER PAMELA L ,  KATI WARREN M ,  KRUEGER ALLAN C ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK THADDEUS S II ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/513 ,  A61P31/12 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

公开(公告)号：MX2011011525A

公开(公告)日：2011-11-18

申请号：MX2011011525

申请日：2010-04-30

Applicant: ABBOTT LAB

Inventor： HAIGHT ANTHONY R ,  ZHANG GEOFF ,  TONG PING ,  FICKES MICHAEL ,  FISCHER CRISTINA ,  HEEMSTRA KATHERINE ,  SANZGIRI YESHWANT ,  SCHMITT ERIC ,  CATRON NATHANIEL ,  ZHOU DELIANG

IPC: A61K9/00 ,  A61K9/48 ,  A61K31/5377 ,  A61K47/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/20

Abstract: Se describe una composición farmacéutica que se puede suministrar por vía oral que comprende un compuesto inhibidor de proteína de la familia de Bcl-2, por ejemplo, ABT-263, un antioxidante de tipo chalcógeno más pesado y un vehículo lípido sustancialmente no acuoso, en la cual dicho compuesto y dicho antioxidante están en solución en el vehículo. La composición es apropiada para administración por vía oral a un individuo en necesidad de lo mismo para tratamiento de una enfermedad caracterizada por sobreexpresión de una o más proteínas anti-apoptóticas de la familia de BcI-2, por ejemplo cáncer.

公开(公告)号：SI2203430T1

公开(公告)日：2011-10-28

申请号：SI200830377

申请日：2008-09-17

Applicant: ABBOTT LAB

Inventor： DONNER PAMELA L ,  RANDOLPH JOHN T ,  KRUEGER ALLAN C ,  BETEBENNER DAVID A ,  HUTCHINSON DOUGLAS K ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  PRATT JOHN K ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/00 ,  A61K31/506 ,  A61K31/513 ,  A61P31/00 ,  C07D401/00 ,  C07D403/00 ,  C07D405/00 ,  C07D409/00 ,  C07D413/00

公开(公告)号：AT512954T

公开(公告)日：2011-07-15

申请号：AT08831558

申请日：2008-09-17

Applicant: ABBOTT LAB

Inventor： DONNER PAMELA L ,  RANDOLPH JOHN T ,  KRUEGER ALLAN C ,  BETEBENNER DAVID A ,  HUTCHINSON DOUGLAS K ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  PRATT JOHN K ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10